http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Yueqi Li ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Sheng Lianchao,Li Min,Li Yueqi,Li Wei 대한전기학회 2021 Journal of Electrical Engineering & Technology Vol.16 No.3
The wind turbine blades have complex stress states, and the load has the characteristics of time-varying and uncertainty. Aiming at the interference problem caused by complex and variable load characteristics to the individual pitch control system, combined with the variable-pitch load characteristics, based on the permanent magnet synchronous motor (PMSM) vector control strategy and LADRC (Auto Disturbance Rejection Speed Controller), an individual pitch speed controller is designed. Linear expansion state observer is built. The control algorithm is deduced and the relationship between each control parameter is analyzed to improve the anti-interference ability of the system to the abrupt load of the pitch. On this basis, the system position tracking controller is built. Finally, a vector control simulation model was built based on MATLB/Simulink, and a speed control simulation was carried out. The simulation results show that LADRC has a strong anti-load disturbance capability, and has better anti-disturbance resistance than PID speed control, and the position controller based on this has a better position tracking eff ect. At the same time, the eff ectiveness of the designed independent pitch speed controller has also been verifi ed through experiments. It is of great signifi cance for improving the conversion effi ciency of wind energy
-
( Lai Wei ),( Mingxiang Zhang ),( Min Xu ),( Wan-Long Chuang ),( Wei Lu ),( Wen Xie ),( Zhansheng Jia ),( Guozhong Gong ),( Yueqi Li ),( Si Hyun Bae ),( Yong-Feng Yang ),( Qing Xie ),( Shumei Lin ),( 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: The efficacy/safety of daclatasvir (pan-genotypic NS5A inhibitor) plus asunaprevir (NS3 protease inhibitor) in interferon (± ribavirin)- ineligible/intolerant patients with chronic HCV genotype-1b infection from mainland China, Korea and Taiwan was investigated in a phase 3, open-label study. Methods: Patients received daclatasvir 60 mg (tablet) once daily plus asunaprevir 100 mg (soft capsule) twice daily for 24 weeks. The primary endpoint was sustained virologic response at post-treatment Week 24 (SVR24). Results: This study treated 159 patients from mainland China (80%), Korea (11%) and Taiwan (9%), including patients with cirrhosis (33%), IL28B non-CC genotypes (40%), and aged ≥70 years (4%). SVR24 was achieved by 91% of patients (100% concordance with SVR12) and was similarly high in all subgroups, e.g. cirrhotic patients (90%), and in patients from mainland China (91%), Korea (94%) and Taiwan (87%). SVR24 was higher in patients without baseline NS5A (L31M/Y93H) resistance-associated variants (RAVs) (n=137/139 [99%]), regardless of the presence (98%) or absence (99%) of cirrhosis, and lower in patients with baseline NS5A RAVs (n=8/19 [42%]). All serious adverse events (AEs) (n=5/159 [3.1%]), grade 4 laboratory abnormalities (n=3/159 [1.9%]) and deaths (n=1/159 [0.6%]) that occurred on-treatment were unrelated to the study drugs; two patients discontinued due to AEs. Treatment was generally well tolerated regardless of cirrhosis status. Conclusions: Daclatasvir plus asunaprevir achieved a high SVR24 rate of 91%, rising to 99% in patients without baseline NS5A RAVs, and was generally well tolerated in cirrhotic and non-cirrhotic interferon (± ribavirin)-ineligible/intolerant patients with HCV genotype-1b infection from mainland China, Korea and Taiwan.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
